S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

$60.28
+0.34 (+0.57%)
(As of 02/28/2024 ET)
Today's Range
$58.96
$60.72
50-Day Range
$52.33
$60.25
52-Week Range
$36.54
$65.89
Volume
114,859 shs
Average Volume
95,816 shs
Market Capitalization
$1.23 billion
P/E Ratio
115.93
Dividend Yield
N/A
Price Target
$72.33

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.0% Upside
$72.33 Price Target
Short Interest
Healthy
1.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
1.16mentions of ANI Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.49 M Sold Last Quarter
Proj. Earnings Growth
-12.36%
From $3.64 to $3.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

91st out of 958 stocks

Pharmaceutical Preparations Industry

27th out of 421 stocks


ANIP stock logo

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

ANIP Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
3 Biotech Stocks to Buy for Investor Security
Ani Pharmaceuticals
ANI Pharma Launches Pentoxifylline Extended-Release Tablets, USP 400mg
ANI Pharmaceuticals: A New Assessment
Double The Returns: 3 Top Stock Picks For 2024
A Boring Biopharma Can Be a Good Bet
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/29/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.33
High Stock Price Target
$73.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+20.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,900,000.00
Pretax Margin
2.94%

Debt

Sales & Book Value

Annual Sales
$316.39 million
Cash Flow
$4.04 per share
Book Value
$17.92 per share

Miscellaneous

Free Float
14,613,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
0.78
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Nikhil  LalwaniMr. Nikhil Lalwani (Age 46)
    President, CEO & Director
    Comp: $1.31M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 53)
    Senior VP of Finance & CFO
    Comp: $751k
  • Mr. James G. Marken (Age 61)
    Senior Vice President of Operations & Product Development
    Comp: $673.23k
  • Mr. Christopher K. Mutz (Age 52)
    Head of Rare Disease
    Comp: $565.17k
  • Mr. Ori Gutwerg (Age 50)
    Senior Vice President of Generics
    Comp: $623.89k
  • Mr. Muthusamy Shanmugam MS R.Ph. (Age 56)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook (Age 50)
    Senior VP, General Counsel & Corporate Secretary
  • Mr. Chad Gassert (Age 48)
    Senior Vice President of Corporate Development & Strategy
  • Ms. Krista L. Davis (Age 51)
    Chief Human Resources Officer
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease














ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price target for 2024?

3 analysts have issued 1 year price objectives for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $72.00 to $73.00. On average, they predict the company's share price to reach $72.33 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2024?

ANI Pharmaceuticals' stock was trading at $55.14 at the start of the year. Since then, ANIP stock has increased by 9.3% and is now trading at $60.28.
View the best growth stocks for 2024 here
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a drop in short interest during the month of February. As of February 15th, there was short interest totaling 213,400 shares, a drop of 11.9% from the January 31st total of 242,200 shares. Based on an average daily trading volume, of 127,100 shares, the days-to-cover ratio is currently 1.7 days.
View ANI Pharmaceuticals' Short Interest
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our ANIP earnings forecast
.

How can I listen to ANI Pharmaceuticals' earnings call?

ANI Pharmaceuticals will be holding an earnings conference call on Thursday, February 29th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-839-8531 with passcode "4470257".

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings data on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to analyst estimates of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. ANI Pharmaceuticals's revenue was up 57.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.46 earnings per share.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.31%), Rubric Capital Management LP (5.50%), Dimensional Fund Advisors LP (2.89%), Global Alpha Capital Management Ltd. (2.85%), Ranger Investment Management L.P. (2.13%) and Thompson Siegel & Walmsley LLC (1.04%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 2/29/2024 by MarketBeat.com Staff